# Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors

> **NCT04169321** · PHASE1 · COMPLETED · sponsor: **Cytosite Biopharma Inc.** · enrollment: 13 (actual)

## Conditions studied

- Solid Tumor, Unspecified, Adult
- Lymphoma

## Interventions

- **DRUG:** Single Arm

## Key facts

- **NCT ID:** NCT04169321
- **Lead sponsor:** Cytosite Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-16
- **Primary completion:** 2025-03-30
- **Final completion:** 2025-06-09
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04169321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04169321, "Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04169321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*